CAR-T cell therapy research

The paper uses synthetic costimulatory domains and machine learning to identify design rules for CARs that enhance cytotoxicity and stemness.

The paper identifies mutations and RNA-binding proteins affecting CD19 splicing and CART-19 therapy resistance through high-throughput mutagenesis and mathematical modeling.

The paper develops drug-gated CAR circuits using NS3 protease domains and FDA-approved inhibitors to enhance CAR T cell therapy safety and specificity.

This paper develops lentiviral vectors with TCR-like expression patterns to generate CAR-T cells with reduced tonic signaling and improved therapeutic profiles.

The paper designs transmembrane domains to control receptor function, showing that oligomeric state affects CAR T cell activity and cytokine release.

This paper introduces a novel antigen-inducible promoter to enhance CAR-T cell activation in low-immunogenic environments, showing improved cytokine expression and T cell proliferation.

This study develops and tests a tBID-based safety switch system for engineered T cells to manage toxicity and persistence, showing up to 90% cell elimination in vitro.

This study develops base-edited CAR T cells to overcome fratricide by removing shared antigens, showing enhanced cytotoxicity against T cell malignancies.

This paper develops hypoxia-sensing CAR T-cells that selectively target solid tumors without off-tumor toxicity using murine xenograft models.

This paper engineers T cells with a two-step positive feedback circuit to kill target cells based on an ultrasensitive antigen density threshold.

The paper constructs a computational model of CAR T cell activation, showing CD28 enhances ERK activation by increasing CD3ζ phosphorylation kinetics.

This paper introduces gene circuits with memory to control gene expression in T cells, demonstrating regulation of CAR expression and T cell activity using an FDA-approved drug.

The paper develops a computational model to explain site-specific phosphorylation kinetics of CARs using phospho-proteomic data and mechanistic modeling.

This study shows that IL18-expressing CAR T cells enhance antitumor immunity, T cell proliferation, and costimulation, while reducing GVHD risk through a novel strategy.